Literature DB >> 31687516

Synthesis, antibacterial properties and bioinformatics computational analyses of novel 8-hydroxyquinoline derivatives.

Mohamed Rbaa1, Siham Jabli2, Younes Lakhrissi1, Mohamed Ouhssine2, Faisal Almalki3, Taibi Ben Hadda3, Saida Messgo-Moumene4, Abbelkader Zarrouk5, Brahim Lakhrissi1.   

Abstract

New heterocyclic derivatives of 8-hydroxyquinoline were prepared and screened as antimicrobial agents. Chemical structures were elucidated and confirmed using different spectroscopic methods such as elemental analysis data, Infrared, Nuclear Magnetic Resonance Spectroscopy. In order to explore their potential biological activity, the "in vitro" antibacterial activity was investigated against [E. coli (ATCC35218), S. aureus (ATCC29213), V. parahaemolyticus (ATCC17802), and P. aeruginosa (ATCC27853)]. The studied compounds exhibited a remarkable antibacterial activity superior to the standard antibiotic (Penicillin G). These new heterocyclic derivatives of 8-hydroxyquinoline, which proved to be potentially effective, can be used as alternative chemical antimicrobial agents applications. It was very interesting to observe that POM (Petra/Osiris/Molinspiration) bioinformatic analyses of the 8-hydroxyquinoline derivative (5) exhibited more important antibacterial activity (MIC = 10-6 mg/mL against V.p and S.a bacteria) and good drug score (DS = 0.71) when compared with Penicillin (DS = 0.33; MIC = 10-3 mg/mL).
© 2019 Published by Elsevier Ltd.

Entities:  

Keywords:  8-hydroxyquinoline; Antibacterial pharmacophore site; Antimicrobial activity; Biochemistry; Characterization; Microbiology; POM (Petra/Osiris/Molinspiration) analyses

Year:  2019        PMID: 31687516      PMCID: PMC6820249          DOI: 10.1016/j.heliyon.2019.e02689

Source DB:  PubMed          Journal:  Heliyon        ISSN: 2405-8440


Introduction

In the recent years, heterocyclic compounds based on 8-hydroxyquinoline become important because of their potential properties in a wide range of fields such as biological activity (Sravanthi and Manju, 2016; Shangguan et al., 2005), anticorrosion (Rbaa et al., 2017, 2019; Rbaa and Lakhrissi, 2019), and complexing properties of metals (Mladenova et al., 2002). The increase of factories and industrial companies will cause serious diseases for man and environment which led to the fact that the use of antibiotics has become indispensable. Moreover, the 8-hydroxyquinoline derivatives are marked several biological properties such as antibiotic, antifungal, antitumor and anticancer (El Faydy et al., 2017). Therefore, the 8-hydroxyquinoline skeleton is an interesting entity for the development and the synthesis of novel biologically active heterocyclic compounds. However, many side effects have been declared by the users of penicillin as antibiotic (Adamkiewicz et al., 2003). Thus, it is urgent to make some changes in the medicinal treatment of bacterial diseases. In this study, we have synthesized novel heterocyclic compounds based on 8-hydroxyquinoline. Their structures have been fully characterized using standard spectroscopic methods such as elemental analysis data, Infrared, and Nuclear Magnetic Resonance Spectroscopy. All the synthesized compounds 1–6 (Fig. 1) have been evaluated "in vitro" for their antimicrobial activity using the following bacterial strains: E. coli, S. aureus, V. parahaemolyticus and P. aeruginosa. The novelty of POM analyses in this work is the identification of antibacterial (N---HO)-pharmacophore site and elucidation the reason why the (8-hydroxyquinolin-5-yl) methyl-4-chlorobenzoate (5) constitutes a better hits than Penicillin itself.
Fig. 1

Synthetic route for the preparation of 8-hydroxyquinoline derivatives 1–6.

Synthetic route for the preparation of 8-hydroxyquinoline derivatives 1–6.

Materials & methods

Chemicals and apparatus

All reagents and solvents used in this study were discussed in a previous work (Feng et al., 2008).

Synthesis of organic compounds

Synthesis of compounds 1–6

Our strategy was to develop a simple and acceptable yielding procedure in a very short time, to prepare the desired 8-hydroxyquinoline derivatives 1–6 (Fig. 1).

Synthesis of compounds 5-CMHQ and 5-HMHQ

5-Hydroxymethyl-8-hydroxyquinoline (5-HMHQ) was prepared by treating 5-chloromethyl-8-hydroxyquinoline hydrochloride (5-CMHQ) with ammonia at room temperature for 15 minutes (Fig. 2). The compound 5-CMHQ was prepared from 8-hydroxyquinoline (HQ) according to a method described in a previous work (Rbaa et al., 2019).
Fig. 2

The reaction for conversion of 5-CMHQ to 5-HMHQ.

The reaction for conversion of 5-CMHQ to 5-HMHQ.

Synthesis of 8-hydroxyquinoline derivatives 1–6

General procedure

A solution of 5-hydroxymethyl-8-quinolinol (0.01 mol), para-substituted benzoic acid (0.01 mol) in absolute THF (50 ml) and a solution of concentrated HCl (37 %), was refluxed under magnetic stirring for 10 h. The reaction was monitored by thin layer chromatography using hexane-acetone (6:4, v/v) as the mobile phase. After completion, the reaction mixture was cooled to room temperature, diluted with water (20 mL), and extracted with dichloromethane (3 × 20 mL). The combined organic layers were dried over anhydrous MgSO4, filtered and the solvent was removed by rotary evaporation under vacuum. The obtained crude residue was washed by acetone, and purified by chromatography on a silica gel column using dichloromethane/hexane (85/15: v/v), and then recrystallized from absolute ethanol (Fig. 3).
Fig. 3

Synthesis of 8-hydroxyquinoline derivatives 1-6.

Synthesis of 8-hydroxyquinoline derivatives 1-6.

Antimicrobial activity

Bacterial strains

The bacteria selected for this study are E. coli responsible for food poisoning and infections (Monod et al., 1952). S. aureus S. aureus causes serious life-threatening complications, such as the infection of the blood, bones or lungs (Meylan et al., 2017). P. aeruginosa is a human pathogen which is more often responsible for nosocomial infections (Appelbaum, 2006) and V. parahaemolyticus (Bej et al., 1999) represents a serious and global threat to human health. They were all provided by the Laboratory of Agro Physiology, Biotechnology, Environment and Quality, Faculty of Sciences, Ibn Tofail University, Kenitra - Morocco. Each bacterium was inoculated into the Mueller-Hinton agar culture medium.

Antibacterial test

Using the agar disk diffusion assay, the antibacterial activity of our products was determined while a bacterial culture of 24 hours was spread on the surface of the Muller-Hinton agar plate. A disc of sterile 6 mm whatmann paper was saturated with 10 μL of 8-hydroxyquinoline derivatives solution under investigation in dimethylsulfoxide as solvent. After 1 h of diffusion, the Petri dishes were incubated at 37 °C for 24 hours and the areas of inhibition of development were measured and compared with those of the Penicillin G reference discs.

Results and discussions

Chemical study

Procedure

All products were synthesized by conventional and simple methods, we have mixed an equimolar amount of 5-hydroxymethyl-8-hydroxyquinoline and 4-substituted benzoic acids in absolute THF in the presence of HClcc. The reaction mixture was refluxed for 10 h under magnetic stirring. The reaction was monitored by a silica thin layer plate and the purification of all the products were obtained and purified by silica gel column chromatography [CH2CH2/hexane,85/15: v/v], and (Fig. 1). The pure product obtained was then triturated via diethyl ether and recrystallized from absolute methanol to yield the (8-hydroxyquinolin-5-yl) methyl-4-alkylbenzoate derivatives 1–6.

Data value, and validation

Preparation of (8-hydroxyquinolin-5-yl) methylbenzoate (1)

Yield 38 %, Aspect White solid, Mp 185-187 °C, Fr 0.35 (C6H14/CH2Cl2, 50/50: v/v), Mm 279.29 g/mol. IR: 1627 (C=C), 3423 (OH), 1798 (C=O). 1H NMR (300 MHz, DMSO-d6): δppm = 4.51 (s, 1H, OH), 4.49 (s, 2H, CH2), 7.56–7.55 (m, 4H, benzene), 7.01-7.32-7.61-8.95-9.87 (m, 5H, Arquinoline). 13C NMR (300 MHz, DMSO-d6): δppm = 63.74 (CH2), 155.79 (ArC-OH), 157.02 (C=O), 129.28–127.78 (ArCHbenzene), 132.00 (ArCbenzene), 110.64-122.15-125.72-153.11 (ArCHquinoline), 129.12-132.51-133.80 (ArCquinoline). Microanalysis (%): Observed, C, (73.71) - H, (5.15) - N, (4.78). Calculated, C, (73.60) - H, (5.30) - N, 4.83.

Preparation of (8-hydroxyquinolin-5-yl) methyl-4-methoxybenzoate (2)

Yield 58 %, Aspect Black solid, Mp 179-181 °C, Fr 0.49 (C6H14/CH2Cl2), 50/50: v/v), Mm 309.32 g/mol. IR: 1648 (C=C), 3456 (OH), 1717 (C=O). 1H NMR (300 MHz, DMSO-d6): δppm = 5.91 (s, 1H, OH), 4.50 (s, 2H, CH2), 3.41 (s, 3H, CH3) 7.43–7.44 (m, 4H, benzene), 7.04-7.32-8.62-8.75-8.76 (m, 5H, Arquinoline). 13C NMR (300 MHz, DMSO-d6): δppm = 45.54 (CH2), 153.32 (ArC-OH), 153.99 (C=O), 21.29 (CH3), 126.23–129.11 (ArCHbenzene), 139.16 (ArCbenzene), 111.04-122.42-123.13-132.25-148.70 (ArCHquinoline), 127.57-136.55-140.09 (ArCquinoline). Microanalysis (%): Observed, C, (69.89) -H, (4.89) - N, (4.53). Calculated, C, (68.50) - H, (4.28) - N, (4.87).

Preparation of (8-hydroxyquinolin-5-yl) methyl-4-methylbenzoate (3)

Yield 49 %, Aspect Black solid, Mp 176-178 °C, Fr 0.45 (C6H14/CH2Cl2), 50/50: v/v), Mm 293.32 g/mol. IR: 1633 (C=C), 3613.58 (OH), 1799 (C=O). 1H NMR (300 MHz, DMSO-d6): δppm = 6.99 (s, 1H, OH), 4.72 (s, 2H, CH2), 7.56-7.58-8.42 (m, 5H, benzene), 7.02-7.37-7.55-8.85-9.79 (m, 5H, Arquinoline). 13C NMR (300 MHz, DMSO-d6): δppm = 61.10 (CH2), 153.06 (ArC-OH), 155.74 (C=O), 126.11–128.49 (ArCHbenzene), 138.07 (ArCbenzene), 111.62-116.10-123.10-134.58-147.98 (ArCHquinoline), 127.59-128.84-139.26 (ArCquinoline). Microanalysis (%): Calculated for C17H13NO3 (279.29). Observed, C, (73.11) - H, (4.69) - N, (5.02); Calculated, C, (73.65) - H, (4.16) - N, (5.73).

Preparation of (8-hydroxyquinolin-5-yl) methyl-4-bromobenzoate (4)

Yield 65 %, Aspect White solid, Mp 201-203 °C, Fr 0.47 (C6H14/CH2Cl2), 50/50: v/v), Mm 358.19 g/mol. IR: 1632 (C=C), 3414 (OH), 1884.41 (C=O). 1H NMR (300 MHz, DMSO-d6): δppm = 5.30 (s, 1H, OH), 3.38 (s, 2H, CH2), 7.59–7.57 (m, 4H, benzene), 7.07-7.43-8.43-8.85-9.84 (m, 5 H, Arquinoline). 13C NMR (300 MHz, DMSO-d6): δppm = 51.42 (CH2), 168.15 (ArC-OH), 169.65 (C=O), 139.28 (C-Br), 129.99–128.56 (ArCHbenzene), 129.50 (ArCbenzene), 110.70-122.14-124.50-148.67 (ArCHquinoline), 127.53-133.10-139.11 (ArCquinoline). Microanalysis (%): Observed, C, (57.00) - H, (3.38) - N, (3.91). Calculated, C, (56.98) - H, (3.24) - N, (3.89).

Preparation of (8-hydroxyquinolin-5-yl) methyl 4-nitrobenzoate (5)

Yield 49 %, Aspect Brown solid, Mp 180-182 °C, Fr 0.41 (C6H14/CH2Cl2), 50/50: v/v), Mm 324.29 g/mol. IR: 1614 (C=C), 3372 (OH), 1709 (C=O). 1H NMR (300 MHz, DMSO-d6): δppm = 4.39 (s, 1H, OH), 4.35 (s, 2H, CH2), 8.12–8.56 (m, 4H, benzene ring), 7.05-7.49-7.56-8.59-8.61 (m, 5H, Ar-quinoline). 13C NMR (300 MHz, DMSO-d6): δppm = 59.84 (CH2), 146.04 (ArC-OH), 152.26 (C=O), 146.48 (C-NO2), 123.66–128.54 (ArCH-benzene ring), 136.2 (ArC-benzene ring), 114.59-119.90-125.92-134.17-145.07 (ArCH-quinoline), 127.84-128.75-139.98 (ArC-quinoline). Microanalysis (%): Observed, C, 62.96 - H, 3.73 -N, 9.64. Calculated, C, 62.87 - H, 3.77 - N, 9.66.

Preparation of (8-hydroxyquinolin-5-yl) methyl 4-chlorobenzoate (6)

Yield 57 %, Aspect Yellow solid, Mp 199-201 °C, Fr 0.37 (C6H14/CH2Cl2), 50/50: v/v), Mm 313.74 g/mol. IR: 1621 (C=C), 3407 (OH), 1736 (C=O). 1H NMR (300 MHz, DMSO-d6): δppm = 5.05 (s, 1H, OH), 4.19 (s, 2H, CH2), 7.63–7.73 (m, 4H, benzene ring), 7.07-7.43-7.58-8.58-8.86 (m, 5H, Ar-quinoline). 13C NMR (300 MHz, DMSO-d6): δppm = 49.38 (CH2), 153.90 (ArC-OH), 167.26 (C=O), 139.32 (C-Cl), 131.82–128.34 (ArCH-benzene ring), 129.50 (ArC-benzene ring), 110.85-122.56-123.36-148.48 (ArCH-quinoline), 127.35-132.46-142.14 (ArC-quinoline). Microanalysis (%): Observed, C, 65.08; H, 3.86; N, 4.46. Calculated, C, 65.02; H, 3.70; N, 4.70.

Preparation of 5-hydroxymethyl-8-hydroxyquinoline (5-HMHQ)

Yield 90 %, Aspect White solid, Mp 138 °C, Fr 0.60 (C6H14/CH2Cl2), 50/50: v/v), Mm 175.18 g/mol. IR: 2022 (C=N), 1636 (C=C), 3496 (OH), 1881.41 (CH2). 1H NMR (300 MHz, DMSO-d6): δppm = 4.66 (s, 2H, CH2), 7.51-7.55-8.44-8.83-8.84 (m, 5 H, ArH). 13C NMR (300 MHz, DMSO-d6): δppm = 23.92 (CH2), 152.40 (C-OH), 111.07-122.13-126.87-127.76-148.24 (Ar-CH), 128.26-133.35-139.33 (Ar-C).

Preparation of 5-chloromethyl-8-hydroxyquinoline hydrochloride (5-CMHQ)

Yield 98 %, Aspect Green solid, Mp > 260 °C, Fr 0.60 (C6H14/CH2Cl2), 50/50: v/v), Mm 230.09 g/mol. IR: 1743 (C=N), 1624 (C=C), 3248 (OH), 1819.34 (CH2). 1H NMR (300 MHz, DMSO-d6): δppm = 3.48 (s, 2H, CH2), 7.64-7.67-8.03-8.06-8.39 (m, 5H, ArH). 13C NMR (300 MHz, DMSO-d6): δppm = 53.88 (CH2), 162.63 (C-OH), 111.72-122.29-127.95-132.92-148.59 (Ar-CH), 129.95-130.60-136.50 (Ar-C). The synthesis of the target compounds in their stable conjugated bicyclic fused rings form was carried out from 5-(hydroxymethyl)-8-hydroxyquinoline () and para-substituted-benzoic acids. The esterification reaction was carried out in two steps, the first one consists in the activation of the carboxylic acid function by HCl in absolute THF as a solvent, and the second one consists in the nucleophilic attack of the primary hydroxyl group on the carbonyl group to yield compounds 1–6.

Bioactivity of compounds 1-6

The compounds were screened for their “in vitro” antimicrobial activity at 10−3 g/mL on four bacterial strains. The bacterial growth inhibition outcome is shown in Fig. 4 and summarized in Table 1. The result obtained for this study showed that all the tested products exhibit an exceptional antimicrobial effect against the bacterial strains compared to antibiotic standard. Compound 1 was an exception and it shows no antimicrobial effect on all the tested bacterial strains. Studies of antibacterial activity in the last decade have demonstrated the importance of quinoline-based heterocyclic compounds as potent antibacterial agents ​(Broch et al., 2010; Fakhfakh et al., 2003). For this purpose, in order to improve the antibacterial activity of 8-hydroxyquinoline, we grafted it with a benzene ring which bears electron donor substituents such as chlorine, bromine, methyl, methoxy and an electron-withdrawing such as the nitro group. From the literature, we have found that the compounds which have electron-withdrawing substituents have a lower activity against Gram-positive and Gram-negative bacteria, than those with electron-donor substituents (Sánchez-Moreno, 2002).
Fig. 4

The antibacterial activity of compounds 1–6 against bacterial strains compared to Penicillin G after 24 h of incubation at 37 °C.

Table 1

Inhibition zone in (mm) of the synthesized compounds 1–6 compared with standard antibiotic Penicillin G against Gram-positive and Gram-negative bacteria in 10−3 g/ML.

CompoundInhibition zone diameter (mm)
Gram-positive bacteria
Gram-negative bacteria
S. aV.E. cP. a
1
21707
3157
41914
5323018
60805
Penicillin G115129

(—): No zone.

The antibacterial activity of compounds 1–6 against bacterial strains compared to Penicillin G after 24 h of incubation at 37 °C. Inhibition zone in (mm) of the synthesized compounds 1–6 compared with standard antibiotic Penicillin G against Gram-positive and Gram-negative bacteria in 10−3 g/ML. (—): No zone. In this series, compounds 2 to 6 substituted on the phenyl ring exhibit excellent antibacterial activity over unsubstituted compound 1. The compound 5 which bears the chlorine in benzene ring shows a good activity against Gram-positives and Gram-negatives strains. These varieties in the antibacterial activity are probably due to the nature of the substituent, the structure of the tested molecules and the bacteria sensitivity. In addition, these products are more active against the Gram-positive bacteria than Gram-negative bacteria. This can be explained by the presence of cytoplasmic membrane in Gram-negative bacteria that block the transfer of compounds through it. These results go in line with the findings of (Sánchez-Moreno, 2002), who showed that the “in vitro” antibacterial activity of the grafted quinolines was more active against Gram-positive than the Gram-negative bacteria (Table 2).
Table 2

MIC of the synthesized compounds 1-6.

CompoundMIC (mg/mL)
V. p.S. a.P. a.E. c.
1NANANANA
210–310–3NANA
310–310–3NANA
410–410–4NANA
510–610–6NA10–4
610–410–3NANA
SD10–310–410–310–3

: Standard Drug (Penicillin G). V. p.: Vibrio parahaemolyticus (ATCC17802); S. a.: Staphylococcus aureus (ATCC29213); P. a.: Pseudomonas aeruginosa (ATCC27853); E. c.: Escherichia coli (ATCC35218).

MIC of the synthesized compounds 1-6. : Standard Drug (Penicillin G). V. p.: Vibrio parahaemolyticus (ATCC17802); S. a.: Staphylococcus aureus (ATCC29213); P. a.: Pseudomonas aeruginosa (ATCC27853); E. c.: Escherichia coli (ATCC35218). Interestingly, in contrast to encouraging activity of compounds 2–6 against the two Gram-positive bacteria (V. p and S. a), we have noted that they are not active (NA) against any one of the two tested Gram-negative bacteria (P. a, and E. c) (Table 2). This indicates that the inhibition of Gram-negative bacteria needs more lipo-soluble antibacterial agents. To get more insights on this point, Petra/Osiris/Molinspiration (POM) analysis has been executed.

POM analyses

The analyses of the physicochemical properties of the compounds 1–6 by using a bioinformtic POM platform-2018 is necessary and useful to identify the type of pharmacophore sites, to evaluate and to predict hits and their efficacy as leading candidates against various diseases (Al-Maqtari et al., 2017; Youssoufi et al., 2015; Lahsasni et al., 2015). The POM physicochemical calculations considered a partition coefficient (cLogP), aqueous solubility, donor hydrogen-bond, and drug-likeness. The Lipinski's rule-of-five was used to evaluate the calculations. To ensure that the oral bioavailability of these products is in a good quality, the topological polar surface (TPSA) should be ˂ 140 Å2. The results of POM physicochemical analyses of compounds 1–6 are shown in Tables 3 and 4. These compounds demonstrated good oral bioavailability (TPSA range = 59–105). Drug score (DS) and Drug-Likeness (DL) analyses were also given for comparison as are shown in Tables 3 and 4.
Table 3

Osiris calculations of toxicity risks of compounds 1–6 and Penicillin G as Standard Drug.

CompoundMWToxicity Risks[a]
Osiris calculations[b]
MUTTUMIRRIREPcLogPcLogSDLDS
1279+++++++++2.96-3.490.370.40
2309++++++++++++2.89-3.51-1.840.47
3293++++++++++++3.30-3.83-0.540.54
4357++++++++++++3.69-4.32-2.740.36
5313++++++++++++3.57-4.233.380.71
6324++++++++++++2.04-3.95-14.30.41
SD[c]334++++++1.54-2.0411.280.33

Highly toxic: (—), Slightly toxic: (+), Not toxic (+++).MUT: Mutagenic, TUM: Tumorigenic, IRRIT: Irritant, RE: Reproductive effective.Sol: Solubility, DL: Druglikness, DS: Drug-Score.: Standard Drug (Penicillin G).

Table 4

Molinspiration calculations of compounds 1–6 and Penicillin G (SD).

CompoundMolinspiration calculations[a]
Drug-likeness[b]
TPSANONHNVVOLGPCRLICMKINRLPIEI
15910248-0.020.03-0.010.01-0.080.12
26910274-0.08-0.04-0.010.03-0.070.06
35910265-0.05-0.06-0.040.01-0.110.05
45910266-0.11-0.06-0.04-0.08-0.170.03
55910262-0.000.02-0.010.02-0.090.08
610510271-0.14-0.04-0.13-0.05-0.15-0.02
SD[c]87202880.10-0.42-0.71-0.370.860.30

TPSA: Total molecular polar surface area; NONH: number of OH—N and O—NH interaction, NV: number of violation of five Lipinsky rules; VOL: volume.GPCRL: GPCR ligand; ICM: Ion Channel Modulator; KI: Kinase Inhibitor; NRL: Nuclear Receptor Ligand; PI: Protease Inhibitor; EI: Enzyme Inhibitor.: Standard Drug (Penicillin G).

Osiris calculations of toxicity risks of compounds 1–6 and Penicillin G as Standard Drug. Highly toxic: (—), Slightly toxic: (+), Not toxic (+++).MUT: Mutagenic, TUM: Tumorigenic, IRRIT: Irritant, RE: Reproductive effective.Sol: Solubility, DL: Druglikness, DS: Drug-Score.: Standard Drug (Penicillin G). Molinspiration calculations of compounds 1–6 and Penicillin G (SD). TPSA: Total molecular polar surface area; NONH: number of OH—N and O—NH interaction, NV: number of violation of five Lipinsky rules; VOL: volume.GPCRL: GPCR ligand; ICM: Ion Channel Modulator; KI: Kinase Inhibitor; NRL: Nuclear Receptor Ligand; PI: Protease Inhibitor; EI: Enzyme Inhibitor.: Standard Drug (Penicillin G).

Conclusion

The analysis of the results obtained by the disk diffusion method shows that the compounds substituted in phenyl ring are more active compared to the non-substituted compound and also compared to the standard antibiotic. The antibacterial activity of the chlorinated compound 5 is more important against Gram-positive bacteria than Gram-negative bacteria such as the S. aureus strain, which is the most sensitive. The bioactivity scores of the series of 1-6 have undergone a comparative POM analyses with Penicillin G indicates that compound 5 needs to be tested in free ligand as antibacterial agent and as potential ligand for ruthenium (II) complexes as more efficient and selective Mycobacterium Tuberculosis Inhibitors (Ben Hadda et al., 2009).

Declarations

Author contribution statement

Mohamed Rbaa, Siham Jabli: Performed the experiments. Faisal Almalki: Conceived and designed the experiments; Performed the experiments; Wrote the paper. Mohamed Ouhssine, Brahim Lakhrissi, Taibi Ben Hadda, Younes Lakhrissi, Saida Messgo-Moumene, Abbelkader Zarrouk: Conceived and designed the experiments; Wrote the paper.

Funding statement

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Competing interest statement

The authors declare no conflict of interest.

Additional information

No additional information is available for this paper.
  11 in total

1.  Synthesis and biological evaluation of substituted quinolines: potential treatment of protozoal and retroviral co-infections.

Authors:  Mohammed A Fakhfakh; Alain Fournet; Eric Prina; Jean-François Mouscadet; Xavier Franck; Reynald Hocquemiller; Bruno Figadère
Journal:  Bioorg Med Chem       Date:  2003-11-17       Impact factor: 3.641

2.  [The kinetics of the biosynthesis of beta-galactosidase in Escherichia coli as a function of growth].

Authors:  J MONOD; A M PAPPENHEIMER; G COHEN-BAZIRE
Journal:  Biochim Biophys Acta       Date:  1952-12

3.  DNA binding specificity and cytotoxicity of novel antitumor agent Ge132 derivatives.

Authors:  Guoqiang Shangguan; Feifei Xing; Xiaogang Qu; Jianhua Mao; Dan Zhao; Xuejian Zhao; Jinsong Ren
Journal:  Bioorg Med Chem Lett       Date:  2005-06-15       Impact factor: 2.823

4.  Synthesis and in vitro antiproliferative activities of quinoline derivatives.

Authors:  Sidonie Broch; Bettina Aboab; Fabrice Anizon; Pascale Moreau
Journal:  Eur J Med Chem       Date:  2010-01-14       Impact factor: 6.514

Review 5.  Indoles - A promising scaffold for drug development.

Authors:  T V Sravanthi; S L Manju
Journal:  Eur J Pharm Sci       Date:  2016-05-27       Impact factor: 4.384

6.  Detection of total and hemolysin-producing Vibrio parahaemolyticus in shellfish using multiplex PCR amplification of tl, tdh and trh.

Authors:  A K Bej; D P Patterson; C W Brasher; M C Vickery; D D Jones; C A Kaysner
Journal:  J Microbiol Methods       Date:  1999-06       Impact factor: 2.363

7.  Carbon Sources Tune Antibiotic Susceptibility in Pseudomonas aeruginosa via Tricarboxylic Acid Cycle Control.

Authors:  Sylvain Meylan; Caroline B M Porter; Jason H Yang; Peter Belenky; Arnaud Gutierrez; Michael A Lobritz; Jihye Park; Sun H Kim; Samuel M Moskowitz; James J Collins
Journal:  Cell Chem Biol       Date:  2017-01-19       Impact factor: 8.116

8.  Synthesis and photophysics of novel 8-hydroxyquinoline aluminum metal complex with 1,3,4-oxadiazole units.

Authors:  Liheng Feng; Xiaoju Wang; Zhaobin Chen
Journal:  Spectrochim Acta A Mol Biomol Spectrosc       Date:  2008-01-10       Impact factor: 4.098

9.  Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination.

Authors:  Thomas V Adamkiewicz; Sharada Sarnaik; George R Buchanan; Rathi V Iyer; Scott T Miller; Charles H Pegelow; Zora R Rogers; Elliott Vichinsky; John Elliott; Richard R Facklam; Katherine L O'Brien; Benjamin Schwartz; Chris A Van Beneden; Michael J Cannon; James R Eckman; Harry Keyserling; Kevin Sullivan; Wing-Yen Wong; Winfred C Wang
Journal:  J Pediatr       Date:  2003-10       Impact factor: 4.406

10.  Anti-tubercular activity of ruthenium (II) complexes with polypyridines.

Authors:  Taibi Ben Hadda; Mehmet Akkurt; Mohamed Filali Baba; Maria Daoudi; Brahim Bennani; Abdelali Kerbal; Zahid H Chohan
Journal:  J Enzyme Inhib Med Chem       Date:  2009-04       Impact factor: 5.051

View more
  5 in total

1.  Facile Synthesis of Functionalized Phenoxy Quinolines: Antibacterial Activities against ESBL Producing Escherichia coli and MRSA, Docking Studies, and Structural Features Determination through Computational Approach.

Authors:  Mahwish Arshad; Nasir Rasool; Muhammad Usman Qamar; Syed Adnan Ali Shah; Zainul Amiruddin Zakaria
Journal:  Molecules       Date:  2022-06-10       Impact factor: 4.927

2.  Crystallographic study, biological assessment and POM/Docking studies of pyrazoles-sulfonamide hybrids (PSH): Identification of a combined Antibacterial/Antiviral pharmacophore sites leading to in-silico screening the anti-Covid-19 activity.

Authors:  Mohammed Chalkha; Asmae Nakkabi; Taibi Ben Hadda; Malika Berredjem; Abdelfattah El Moussaoui; Mohamed Bakhouch; Mohamed Saadi; Lahcen El Ammari; Faisal A Almalki; Hamid Laaroussi; Violeta Jevtovic; Mohamed El Yazidi
Journal:  J Mol Struct       Date:  2022-06-28       Impact factor: 3.841

3.  Synthesis, Biochemical Characterization, and Theoretical Studies of Novel β-Keto-enol Pyridine and Furan Derivatives as Potent Antifungal Agents.

Authors:  Said Tighadouini; Smaail Radi; Redouane Benabbes; Moulay Hfid Youssoufi; Sergey Shityakov; Mohamed El Massaoudi; Yann Garcia
Journal:  ACS Omega       Date:  2020-07-09

4.  In vitro potential antiviral SARS-CoV-19- activity of natural product thymohydroquinone and dithymoquinone from Nigella sativa.

Authors:  Eman R Esharkawy; Faisal Almalki; Taibi Ben Hadda
Journal:  Bioorg Chem       Date:  2022-01-01       Impact factor: 5.307

Review 5.  Recent Advances in the Synthesis and Biological Activity of 8-Hydroxyquinolines.

Authors:  Haythem A Saadeh; Kamal A Sweidan; Mohammad S Mubarak
Journal:  Molecules       Date:  2020-09-21       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.